
Charles E. Cooley
Examiner (ID: 18400, Phone: (571)272-1139 , Office: P/1774 )
| Most Active Art Unit | 1774 |
| Art Unit(s) | 1797, 1774, 1723, 2402, 1754, 3405 |
| Total Applications | 4063 |
| Issued Applications | 3143 |
| Pending Applications | 300 |
| Abandoned Applications | 659 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18844511
[patent_doc_number] => 20230406915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => ANTI-DKK2 ANTIBODY, COMPOSITION CONTAINING ANTI-DKK2 ANTIBODY, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/255567
[patent_app_country] => US
[patent_app_date] => 2021-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255567
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/255567 | ANTI-DKK2 ANTIBODY, COMPOSITION CONTAINING ANTI-DKK2 ANTIBODY, AND USE THEREOF | Nov 15, 2021 | Pending |
Array
(
[id] => 18664883
[patent_doc_number] => 11771748
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Methods for treating tumor-induced osteomalacia
[patent_app_type] => utility
[patent_app_number] => 17/525738
[patent_app_country] => US
[patent_app_date] => 2021-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 30
[patent_no_of_words] => 42346
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17525738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/525738 | Methods for treating tumor-induced osteomalacia | Nov 11, 2021 | Issued |
Array
(
[id] => 18808632
[patent_doc_number] => 20230382966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23
[patent_app_type] => utility
[patent_app_number] => 18/032479
[patent_app_country] => US
[patent_app_date] => 2021-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032479
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/032479 | NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 | Oct 25, 2021 | Pending |
Array
(
[id] => 17520542
[patent_doc_number] => 20220106391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/496597
[patent_app_country] => US
[patent_app_date] => 2021-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49031
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496597
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/496597 | ANTI-NGF ANTIBODIES AND METHODS OF USE THEREOF | Oct 6, 2021 | Abandoned |
Array
(
[id] => 18770853
[patent_doc_number] => 20230365654
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING
[patent_app_type] => utility
[patent_app_number] => 18/030089
[patent_app_country] => US
[patent_app_date] => 2021-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6123
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030089
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/030089 | METHOD OF TREATMENT OF FIBROSIS AND WOUND HEALING | Oct 3, 2021 | Pending |
Array
(
[id] => 18771145
[patent_doc_number] => 20230365956
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/029043
[patent_app_country] => US
[patent_app_date] => 2021-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15462
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029043
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | Sep 30, 2021 | Pending |
Array
(
[id] => 18787284
[patent_doc_number] => 20230375552
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER
[patent_app_type] => utility
[patent_app_number] => 18/247144
[patent_app_country] => US
[patent_app_date] => 2021-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18247144
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/247144 | INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER | Sep 28, 2021 | Pending |
Array
(
[id] => 18817521
[patent_doc_number] => 20230391861
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY
[patent_app_type] => utility
[patent_app_number] => 18/026546
[patent_app_country] => US
[patent_app_date] => 2021-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18951
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026546
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/026546 | POTENT BINDING AGENTS FOR ACTIVATION OF THE HEDGEHOG SIGNALING PATHWAY | Sep 26, 2021 | Pending |
Array
(
[id] => 17336037
[patent_doc_number] => 20220002368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/478628
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478628
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478628 | DUAL FUNCTION PROTEINS COMPRISING FGF21 MUTANT PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sep 16, 2021 | Abandoned |
Array
(
[id] => 17336036
[patent_doc_number] => 20220002367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/478600
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10578
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478600
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478600 | LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sep 16, 2021 | Abandoned |
Array
(
[id] => 18753981
[patent_doc_number] => 20230357338
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY
[patent_app_type] => utility
[patent_app_number] => 18/245453
[patent_app_country] => US
[patent_app_date] => 2021-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245453
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245453 | FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY | Sep 14, 2021 | Pending |
Array
(
[id] => 17314500
[patent_doc_number] => 20210403548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/471702
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471702
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/471702 | TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF | Sep 9, 2021 | Pending |
Array
(
[id] => 17290985
[patent_doc_number] => 20210386824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => Nucleic Acids Encoding FGF21-Fc Fusion Proteins
[patent_app_type] => utility
[patent_app_number] => 17/410307
[patent_app_country] => US
[patent_app_date] => 2021-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23877
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410307
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/410307 | Fibroblast growth factor-21-Fc fusion proteins | Aug 23, 2021 | Issued |
Array
(
[id] => 17387058
[patent_doc_number] => 20220034910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 17/403078
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31936
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17403078
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/403078 | BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE | Aug 15, 2021 | Abandoned |
Array
(
[id] => 18753978
[patent_doc_number] => 20230357334
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => COMPOSITION OF DRUG AND WILD-TYPE CELL-PENETRATING PEPTIDE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/021868
[patent_app_country] => US
[patent_app_date] => 2021-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11130
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021868
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021868 | COMPOSITION OF DRUG AND WILD-TYPE CELL-PENETRATING PEPTIDE DERIVATIVE | Aug 15, 2021 | Pending |
Array
(
[id] => 18650795
[patent_doc_number] => 20230296630
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE
[patent_app_type] => utility
[patent_app_number] => 18/021021
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18498
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021021
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021021 | MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | Aug 11, 2021 | Pending |
Array
(
[id] => 18727122
[patent_doc_number] => 20230341403
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER
[patent_app_type] => utility
[patent_app_number] => 18/005082
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7405
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005082
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/005082 | METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER | Jul 13, 2021 | Pending |
Array
(
[id] => 17343698
[patent_doc_number] => 20220010029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => HYBRIDOMA CELL STRAIN THAT SECRETS ANTI-DINITOLMIDE MONOCLONAL ANTIBODIES AND THE APPLICATION OF HYBRIDOMA CELL STRAIN
[patent_app_type] => utility
[patent_app_number] => 17/368108
[patent_app_country] => US
[patent_app_date] => 2021-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2767
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17368108
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/368108 | Anti-dinitolmide monoclonal antibodies and hybridoma cell strain that secretes them | Jul 5, 2021 | Issued |
Array
(
[id] => 17343690
[patent_doc_number] => 20220010021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
[patent_app_type] => utility
[patent_app_number] => 17/365183
[patent_app_country] => US
[patent_app_date] => 2021-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 552
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/365183 | FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides | Jun 30, 2021 | Issued |
Array
(
[id] => 17156125
[patent_doc_number] => 20210317176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-14
[patent_title] => FG21 MUTANTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/357444
[patent_app_country] => US
[patent_app_date] => 2021-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17357444
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/357444 | Methods of treating non-alcoholic steatohepatitis using FGF21 mutants | Jun 23, 2021 | Issued |